01 December 2012

German-based SCHOTT to expand capacity at its plant in Zavolzhe, Russia

- Increase production capacity by more than 50 percent 
- Russian pharma industry has experienced double-digit growth

Mainz/Moscow - 26 November 2012 – SCHOTT Pharmaceutical Packaging continues to experience growth in Russia and now plans to increase the production capacities at its plant in Zavolzhe by more than 50 percent. 

“Expanding our presence in Russia represents an important strategic step for the benefit of our customers,” emphasizes Prof. Udo Ungeheuer, Chairman of the Board of Management of SCHOTT AG. “We are seeing continued growth in demand for locally manufactured primary packaging that also meets all of the international standards for quality. This will result in shorter delivery routes and better export opportunities for our customers. In other words, by pursuing a consistent investment strategy, we will be helping our customers in the Russian pharmaceutical industry to achieve their own growth and quality objectives,” he adds. 

The Russian pharmaceutical industry has experienced double-digit growth in recent years. State initiatives like the government’s “Pharma 2020” strategy that seeks to encourage local manufacturing of high-quality medications according to the GMP standard (“Good Manufacturing Practice”) will continue this development. SCHOTT became the first international manufacturer in Russia to open a new GMP-compliant pharmaceutical packaging plant in the spring of 2011 and it has been a great success. After all, the order situation has made it necessary to expand capacities earlier than expected. By setting up new production lines for vials and ampoules, SCHOTT has now demonstrated consistency in taking the next step toward continuing to offer its Russian customers shorter delivery times. 

“Thanks to our many years of experience and high international standards for quality, SCHOTT is the right partner for the ambitious and growing Russian pharmaceutical industry,” Sackhoff adds. 

GMP will be required by law for all companies that manufacture in Russia starting in 2014 and SCHOTT has the necessary know-how on helping its customers to establish GMP-certified manufacturing thanks to its 125 years of experience and global manufacturing network,” Ungeheuer concludes. 

SCHOTT Pharmaceutical Systems is one of the world’s leading suppliers of glass tubing and primary packaging for the pharmaceutical industry. It has five glass tubing production sites and fifteen sites for pharmaceutical packaging spread over four continents. 

SCHOTT is an international technology group with more than 125 years of experience in the areas of specialty glasses and materials and advanced technologies. The SCHOTT Group workforce of around 17,000 employees generated worldwide sales of approximately 2.9 billion euros for the 2010/2011 fiscal year. SCHOTT AG, with its headquarters in Mainz (Germany) is owned by the Carl Zeiss Foundation. 

Source: SCHOTT AG